Year-end Sale % OFF 
Abstract
BackgroundDysregulation of long non-coding RNAs (lncRNAs) is involved in development of prostate cancer. However, the molecular mechanisms of many lncRNAs in prostate cancer have not been studied yet.MethodsThe lncRNA Fer-1-like protein 4 (FER1L4) expression was explored in prostate tumors and normal prostate tissues by RT-qPCR and bioinformatic analysis. Overexpression of FER1L4 was performed to evaluate its role in prostate cancer cell proliferation and survival. The molecular mechanism of FER1L4 was investigated by dual luciferase reporter assay, RNA pull down assay, western blotting and RT-qPCR.ResultsIt was found that FER1L4 was lower in prostate cancer tissues than normal tissues. Higher expression of FER1L4 was associated with prostate cancer tissues of early stage (AJCC stage I/II). Overexpression of FER1L4 inhibited cell proliferation and promoted cell apoptosis in prostate cancer cells. Bioinformatic analysis, RT-qPCR, RNA pull down assay and dual luciferase assay showed that FER1L4 upregulated F-box/WD repeat-containing protein 7 (FBXW7) tumor suppressor via sponging miR-92a-3p. Silencing of FBXW7 reversed the cell phenotypes caused by FER1L4 overexpression in prostate cancer cells.ConclusionThe data demonstrated that FER1L4, a downregulated lncRNA in prostate cancer, was pivotal for cell proliferation and survival of prostate cancer. The study provided new sights into understanding of the signaling network in prostate cancer and implied that FER1L4 might be a biomarker for patients with prostate cancer.
Highlights
Dysregulation of long non-coding RNAs is involved in development of prostate cancer
Bioinformatic analysis, RNA pull down assay, western blotting and dual luciferase reporter assay were applied to study the molecular mechanism of Fer-1-like protein 4 (FER1L4) in prostate cancer cells
FER1L4 was significantly decreased in prostate cancer tissues (n = 492) compared with normal prostate tissues (n = 152) (Fig. 1a)
Summary
Dysregulation of long non-coding RNAs (lncRNAs) is involved in development of prostate cancer. The molecular mechanisms of many lncRNAs in prostate cancer have not been studied yet. Multiple studies revealed that lncRNA were implicated in cancer pathogenesis and progression [10,11,12]. Many lncRNAs were identified as oncogenes or tumor suppressors in prostate cancer [14, 15]. LncRNA HOXD-AS1 was highly expressed in castration-resistant prostate cancer and inhibited cell proliferation and chemotherapy resistance via recruiting WDR5 [14]. LncRNA MEG3 sponged miR-9-5p, upregulated QKI-5 and suppressed prostate cancer cell proliferation, migration, invasion and induced apoptosis [16]. The biological role and molecular mechanism of FER1L4 in prostate cancer is unknown
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
